Aims & Scope
The International Journal of Neuropsychotherapy (IJNPT) is an open access, online journal that considers manuscripts on all aspects of integrative, biopsychosocial issues related to psychotherapy. IJNPT aims to explore the neurological or other biological underpinnings of mental states and disorders to advance the therapeutic practice of psychotherapy.

Our mission is to provide researchers, educators and clinicians with the best research from around the world to raise awareness of the neuropsychotherapy perspective to mental health interventions.

Article Categories:
In agreement with the scope of the journal, papers submitted must be associated with the neurological or other biological underpinnings of mental states/disorders, or advances in any biological/psychological/social understanding of interrelatedness and impact on psychopathology or normative mental states and how these advances in knowledge impact therapeutic practice.

Empirical Studies: Original research with solid practical and theoretical advances for neuropsychotherapy.

Case Studies: Case studies highlighting neuropsychotherapy theory and methodology in clinical application.

Articles: Theoretical articles using current research to advance theory, or a description of current theory (Theory). Methodological articles describing new approaches or changes to existing methods in neuropsychotherapy (Methodology), are welcome. Other articles include: Perspectives (brief accessible pieces covering a broad array of topics relevant to neuropsychotherapy); Applied NPT (brief accessible pieces describing the authors clinical application of neuropsychotherapy);

Review Articles (Literature Reviews): Meta-analytical papers and other such review research critically evaluating previously published material directly related to Neuropsychotherapy.

Letters & Research Notes: Short descriptions of important current research findings associated with, and important to, a biopsychosocial understanding of psychopathology and therapeutic interventions.

Submission Guidelines
Research papers should be formatted to the general IMRAD layout and follow APA style. For a review of acceptable format you can visit the International Committee of Medical Journal Editors articles on Preparing a Manuscript for Submission to a Biomedical Journal.

Manuscripts must be sent via email to editor@IJNPT.net and accompanied by a cover note, which should include the following information:

- A full statement to the editor, about all submissions and previous reports that might be regarded as redundant publication of the same or very similar work. Any such work should be referred to specifically and referenced in the new paper. Copies of such material should be included with the submitted paper to help us address the situation.
- A statement of financial or other relationships that might lead to a conflict of interest, if that information is not included in the manuscript itself.
- A statement that the manuscript has been read and approved by all the authors, and that each author believes that the manuscript represents honest work.
- The name, address, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs, if that information is not included in the manuscript itself.

Open Access Policy
The International Association of Neuropsychotherapy (IACN) provides open access to the International Journal of Neuropsychotherapy and all of its content on the principle that making research freely available to the public supports a greater global exchange of knowledge, increased readership, and increased citation of our author’s work.

Peer-Review Process
After an initial filtering by the Chief Editor, manuscripts will be reviewed by two recognised experts. Peer reviewers will give recommendations to the editors as to the validity, coherence and originality of the manuscript and if it should be accepted, revised, or rejected. Final decisions will be made by the Chief Editor in collaboration with advisors. The review process is at the total discretion of the editors and publisher.

Submission Fee & Copy Editing
This journal is open access, free to the public to maximise reach, and does not generate any revenue for the publisher. There are, however, costs associated with managing and publishing this journal and a successful submission will be charged a publishing fee of $0.08/word to cover all costs including experienced academic editors ensuring the highest standard of manuscripts. This is the only fee charged to the author(s). Articles should be submitted as a Word document for ease of editing and commenting by reviewers. All final editing will be passed by the author for final agreement before publishing.

Redundancy & Copyright
Manuscripts that have been published in another journal or citable form will be considered redundant and will not be considered. Authors are responsible for ensuring material submitted does not infringe existing copyrights or the rights of a third party. We do not require the transfer of copyright to be published in our journal. We only require an agreement for the rights to publish, as we do for our magazine and website. This standard agreement is found here: Publishing Agreement. This form must be completed and accompany your submission.

Conflict of Interest
When authors submit a manuscript, whether an article or a letter, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. For a full explanation of potential conflicts of interest please refer to the ICMJE Conflicts of Interest page. We have adopted the Uniform Disclosure Form to make it easier for authors to report potential conflicts of interest. This form must be completed and an electronic copy sent to us via email with your submission (do not send it to ICMJE). The Disclosure Form can be downloaded directly from here: http://www.icmje.org/coi_disclosure.pdf

Citation Linking
The IACN is a publisher member of Crossref, the official DOI registration agency for scholarly publications. Articles published in the IJNPT will be referenced with their own unique digital object identifier, providing the article with a persistent, actionable identifier for that piece of intellectual property. We encourage authors to include DOIs in their reference list when a DOI is available for a particular citation. Our online publication will provide hyperlinks with each specified DOI.

Video Abstracts & Introductions
We are encouraging authors to produce video abstracts or introductions to their papers. This is by no means compulsory, but is a highly effective way to engage readers and effectively communicate the core elements of your paper. The video should be less than five minutes long and communicate the main thrust of your paper. The video may be displayed at a low resolution, so please do not include small text or diagrams that would be difficult to see at low resolution. You must not use anything in your video that you do not have copyright to (music, images, insignias, and so on). The video will be considered to be under nonexclusive copyright terms. If you are interested in producing a video abstract or introduction please let us know with your submission.

Further Information
We follow the International Committee of Medical Journal Editors guidelines for biomedical journals.
EDITORIAL TEAM

CHIEF EDITOR
Roger Mysliwiec

MANAGING EDITOR
Jonathan Wills

GUEST PEER REVIEWER
Heinrich Wilhelm Roth

COPY EDITOR
Tina Pentland

ADVISORY BOARD
Roger Mysliwiec (Chair)
Peter Kyriakoulis
Rita Princi
Mary Bowles
Daren Wilson
Peter Janetzki
Dionne Shnider
Matthew Dahlitz

PUBLISHER
International Association of Applied Neuroscience

DISCLAIMER

The International Journal of Neuropsychotherapy (IJNPT) ISSN 2202-7653, is an open access online journal published by the International Association of Applied Neuroscience. The publisher makes every effort to ensure the accuracy of all the information contained in this publication. However, the publisher, and its agents, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the information herein. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of, or endorsed by, the publisher. The accuracy of the information in this journal should be independently verified with primary sources of information. The publisher shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the information in this journal.

Our mission is to provide researchers, educators and clinicians with the best research from around the world to raise awareness of the neuropsychotherapeutic perspective for mental health interventions. For further information about this journal and submission details please email journal@iaan.com.au

International Journal of Neuropsychotherapy
Volume 7, Issue 1 (2019)

ISSN 2202-7653
ISBN-13 978-1719190374
ISBN-10 1719190372

Published by The International Association of Applied Neuroscience (IAAN)
www.iaan.com.au
Neuroscience-based cognitive therapy is a new science- and evidence-based psychotherapy approach that attempts to integrate certain psychophysiological methods such as monitoring of electrodermal activity (EDA) and skin conductance biofeedback (BFB) with selected cognitive techniques to treat mental disorders. This article describes EDA as a psychophysiological parameter that can support a neurobiological model of post-traumatic stress disorder (PTSD). BFB was proposed as an additional therapeutic technique that can improve the efficacy of the cognitive therapy protocol. A single-case experimental study was undertaken, in which a patient affected by PTSD was treated for four months with BFB to augment his cognitive therapy. The results obtained after the treatment and a two-year follow-up demonstrate that neuroscience-based cognitive therapy is efficacious when used in the treatment of PTSD. The positive results demonstrate that neuroscience-based cognitive therapy is not only science-based but also evidence-based.

Keywords: post-traumatic stress disorder, neuroscience-based cognitive therapy, biofeedback, electrodermal activity

Submitted: October, 2018 • Accepted for publication: January 2019 • Published online: February 2019

Author Note
Tullio Scrimali, Department of Clinical Psychology, University of Catania, Catania, Italy.

Funds and logistics for this study were provided by the Istituto Superiore per le Scienze Cognitive, Enna, Italy.

Correspondence concerning this article should be addressed to Tullio Scrimali, University of Catania, Catania, Italy. Email: tscrima@tin.it

Acknowledgements
The author would like to thank guest peer reviewer Heinrich Wilhelm Roth for his feedback and comments.

Neuroscience-based cognitive therapy, which was developed by Scrimalli (2012), is a new, integrated approach to the treatment of mental disorders.

The aim of this *fourth-wave* cognitive therapy, as named by Arthur Freeman (2012), is that it is to be science-based and evidence-based, and that it is grounded in neurobiology to develop a neuroscience-based psychopathology (Scrimalli, 2008). Neuroscience-based cognitive therapy also attempts to integrate certain psychophysiological methods such as monitoring of electrodermal activity (EDA) and biofeedback (BFB) with certain cognitive and behavioral techniques. The aim is to develop clinical protocols that are both science-based and evidence-based (Scrimalli, Tomasello, & Sciuto, 2015).

In this article, the author describes his work applying the new paradigm of neuroscience-based cognitive therapy to better understand and treat post-traumatic stress disorder (PTSD).

A neurobiological model of the psychopathology of PTSD is first described to establish a tailored integrated treatment for PTSD that includes certain applied neuroscience techniques, such as monitoring of EDA and BFB.

**The Neurobiology and Applied Psychophysiology of PTSD**

Scaglione and Lockwood recently presented a neurocognitive model of PTSD by incorporating findings of frontal cortical and subcortical dysregulation after exposure to trauma (Scaglione & Lockwood, 2014). Other researchers have demonstrated reduced medial frontal activity and impaired frontal modulation in the amygdala in PTSD (Elzinga & Bremner, 2002; Liberzon & Sripada, 2008).

EDA is a biological parameter that provides information regarding the psychological condition of an individual (Prokasy & Raskin, 1973). EDA reflects the level of functioning in the sweat glands, which is linked to the dynamic processes of the central and peripheral nervous systems (Scrimalli, 2012; Scrimalli et al., 2015). EDA is a very sensitive marker of any tonic (i.e., the skin conductance level; SCL) and transient (i.e., the skin conductance response; SCR) changes in arousal, which is one of the most important characteristics of PTSD (American Psychiatric Association, 2013). In neurobiological terms, EDA provides reliable information regarding activation of the amygdala and altered modulation exerted by certain frontal areas of the brain (Boucsein, 1996; LeDoux, 1996; Nagai, Cristchley, Featherstone, Trimble, & Dolan, 2004). In fact, when patients affected by PTSD are asked to imagine a threatening situation, their electrodermal responses (i.e., SCRs) have been found to be greater than those of the control subjects (Orr, Metzger, & Pitman, 2002).

According to the neurobiological perspective (Scaglione & Lockwood, 2014), PTSD is a syndrome characterized by three main clusters of symptoms, as follows:

- **re-experiencing** (flashbacks, intense negative emotions and reminders);
- **avoidance** (behavioral avoidance, avoidance of thoughts and images); and
- **hyperarousal symptoms** (difficulty sleeping, excessive alertness, easily startled responses).

In terms of applied neuroscience, EDA is a good marker of PTSD that can document certain biological aspects of re-experiencing and hyperarousal. When using this parameter, it is possible to document the intense physiological reactions to reminders and most hyperarousal symptoms. Clinical monitoring of EDA can therefore be useful for studying certain neurobiological aspects and symptomatology. Obviously, the outcome should also be documented according to any changes in this parameter. A demonstration of these two topics was one of the goals of the study.

**From Neurobiology and Applied Psychophysiology to BFB**

Using neuroscience in trauma therapy constitutes a very recent approach to the treatment of PTSD (Uhernik, 2017). BFB appears to be an ideal choice to augment the cognitive therapy used with PTSD patents undergoing treatment. Some preliminary studies integrating BFB with cognitive-behavioral therapy (CBT) to treat PTSD have shown positive results (Silver, Brooks, & Obenchain, 1995), and the use of BFB in the treatment of PTSD was scored as
Level 2 (i.e., possibly efficacious) in a study by Yucha and Montgomery (2008). Despite the potentially great value of BFB in the treatment of PTSD, however, the evidence to date is insufficient regarding the efficacy of this treatment in PTSD.

Integrating BFB into psychotherapy is one of the main goals of neuroscience-based cognitive therapy. A single-case research study was therefore carried out to evaluate the efficacy of EDA monitoring and EDA–BFB in the treatment of patients affected by PTSD.

**Methods**

This study was conducted according to the methodological principles adopted in $n = 1$ case-study research (McLeod, 2010).

A 52-year-old male patient was treated for eight months with an integrated electrodermal BFB–CBT protocol.

Three months before starting the treatment, the patient had experienced a traumatic event. The patient was driving along a leafy avenue in the Sicilian town where he lived. There was a windstorm. While stopped at traffic lights, a large tree was uprooted by the violence of the tornado and fell several meters onto his car. The patient had only enough time to lie sideways across the passenger seat before the car’s roof was completely crushed. He remained in this position (with several broken ribs) for several hours until emergency personnel were able to pull the tree off the car. The car itself was destroyed.

During the following weeks he started experiencing intrusive memories of the event. In particular, he saw the tree flying toward his car and crushing it. He also experienced similar recurring dreams that woke him from his sleep. He experienced intense anxiety reactions every time he drove his car. He complained of severe reactions of anxiety every time he saw a tree or felt wind.

Unfortunately, his primary care physician did not correctly diagnose these symptoms as PTSD and criticized the patient for not being “man enough” to recover quickly from the accident. The patient then became depressed and exhibited impaired self-esteem. He also experience various symptoms associated with hyperarousal, such as hypervigilance, poor concentration, and sleep problems.

The symptoms continued for three months until the patient decided to seek help at the Applied Neuroscience and Cognitive Behavioral Therapy Unit of the ALETEIA Clinical Center in Enna, Italy, where he was diagnosed according to the criteria described in the fifth edition of the *Diagnostic and Statistical Manual for Mental Disorders* (American Psychiatric Association, 2013).

Since a new neuroscience-based cognitive therapy protocol for PTSD had recently been developed at the Center, the patient was offered this treatment. He was informed that because this therapy was experimental, it would be provided free. The patient read and signed an informed-consent document, which is available on file at the ALETEIA Clinical Center.

The research study was conducted according to the laws and regulations of Italy and any applicable international norms and standards, primarily, the Declaration of Helsinki (World Medical Association, 2013). The study protocols were reviewed and approved by the Committee for Clinical Research at the ALETEIA Clinical Center. Funds and logistics for the research study were provided by the Istituto Superiore per le Scienze Cognitive, Enna, Italy, which is a nonprofit, private institution according to its philanthropic mission.

The patient attended weekly sessions as an outpatient at the applied neuroscience and CBT unit at the ALETEIA Clinical Center for a period of four months (a total of 16 sessions). During these sessions, the EDA and BFB trials were monitored.

Treatment was based on electrodermal BFB, which was used as an instrument for desensitization and reprocessing the trauma.

The MindLAB Set system produced by Psychotech (http://www.psychotech.it) was utilized. The hardware consisted of a pair of electrodes and an interface device for data collection and transfer to a computer. Two integrated programs, MindSCAN and Psychofeedback, were used to monitor and record the EDA (MindSCAN) during weekly BFB sessions (Psychofeedback).

At each session, the patient was asked to sit in a comfortable chaise longue. The temperature in the
A laboratory was monitored frequently and maintained at 22°C (winter) and 24°C (summer).

A monitor and two speakers were positioned in front of the patient to provide visual and acoustic feedback related to the SCL.

The treatment was conducted according to the original CBT protocol with a number of additional steps that integrated the electrodermal BFB with the PTSD treatment model proposed by Ehlers, Clark, Hackmann, McManus, and Fennell (2005). The developed protocol included the following steps:

- psychoeducation;
- auto-observation and monitoring;
- learning to lower arousal according to BFB;
- image exposure;
- imagery re-scripting; and
- cognitive restructuring.

**Psychoeducation.** It was explained to the patient that he was experiencing a common mental disorder rather than a “stupid habit”, as his physician previously stated. He was told that PTSD is quite frequent in individuals who have experienced a trauma similar to his. He was informed that he was not cured, but that after adequate treatment consisting of cognitive therapy, he would recover.

**Auto-observation and monitoring.** The patient observed through the computer monitor that his levels of arousal, as measured by monitoring the SCL, were high in comparison with the normative database. He was asked to imagine the scene of the accident, and a further increase in arousal was observed. Thus, the patient realized that his emotional and physical disturbance was provoked by a flashback of the trauma.

**Modification of instructions.** The patient was taught emotional self-regulation through BFB. The treatment was conducted as follows.

The patient was encouraged to lower arousal by acting at thinking, imagery, emotion, and somatic levels. He was further encouraged to establish different types of cognitive, emotional, and bodily attitudes. As the graph of the SCL was drawn on the monitor and reinforcement sounds were presented, the patient was encouraged to understand and memorize the specific set realized in that specific moment in his mind and body. Similarly, when both visual and acoustic feedback informed the patient that his arousal was increasing, he was trained to understand the type of negative attitude he was producing and avoid it.

The patient developed an understanding of a coping strategy that was useful in reducing arousal. Then he was encouraged to generalize this strategy to real-life situations. At the beginning of each session, before practicing BFB, the SCL was measured and the recorded values were discussed with the therapist. When the SCL was high (i.e., when it indicated a warning sign of stress), the patient was encouraged to identify the reason for the increased arousal and attempt to reduce the stress. The training was intuitive, comfortable, and interesting for the patient.

**Image exposure.** During some sessions, the patient was asked to lower arousal via BFB and imagine the scene causing his trauma.

**Imagery re-scripting.** While reactivating the image of the trauma, the patient was encouraged to change something about the previous script. In fact, during these sessions, the patient began to change his internal dialogue, telling himself: *Really, I was smart and quick-acting when I changed my position in the car before the tree crushed it.* This change increased his sense of mastery and self-esteem and improved his mood.

**Cognitive restructuring.** Due to the BFB training, and some sessions based on Socratic dialogues, the patient started to change certain automatic thoughts and schemas as follows:

*I am stupid and weak because I am not able to overcome this problem by myself!*

*It was my responsibility when I decided to drive in that place during a storm!*

He developed a sense of mastery and constructed a positive sense of what occurred. The new sense was as follows:

*Trauma occurs, and the victim is not responsible for this!*
They should be helped to recover from a disorder they developed, and this is not evidence of being weak but rather a mental disorder named PTSD.

**Materials**

The outcomes for the patient were evaluated by the following assessment instruments:

- Impact of Event Scale (Horowitz, Wilner, & Alvarez, 1979)
- Beck Anxiety Inventory (Beck, 1993)
- Beck Depression Inventory (Beck, 1996)
- SCL registered by MindLAB Set (Scrimali, 2012).

**Results**

To create a time-series analysis, three sets of data were collected every week for all measures at the following time points: baseline, end of treatment, and follow-up after two years. The data are reported in Tables 1, 2, 3, and 4, and illustrated in the graphs in Figures 1, 2, 3, and 4.

A statistical analysis of the data reported in the tables and graphs was carried out, using the time-series simulation modeling analysis developed by Borckardt et al. (2007).

The three values of the baseline, which were collected each week before starting the treatment, and the six values collected at the end of the treatment, and at a two-year follow-up, were compared. All four series of data exhibited a significant improvement that was maintained after two years.

The EDA values at the beginning and end of the treatment were also compared using the Student's t-test. This analysis was carried out automatically by the MindSCAN software. The difference was significant (p < 0.05); see Figure 5.

**Discussion**

The project integrating applied neuroscience and BFB into a CBT protocol for the treatment of PTSD has been positive. The following goals were achieved:

- Lowering basic arousal without using any drug treatment.
- Lowering and maintaining low arousal during traumatic image exposure.
- The setting in which the CBT was augmented by the BFB was comfortable for both the patient and the therapist.
- Re-scripting the scene of the trauma created a sense of safety and calmed the patient, and the patient developed mastery due to the practice of BFB.
- The cognitive restructuring, imagery, acceptance of the trauma, and narrative re-scripting were successful and enhanced the sense of mastery and self-control learned by the patient during the BFB sessions.
- The results were very stable as demonstrated by the two-year follow-up analysis.

**Conclusion**

This research study has demonstrated that integrating applied neuroscience and BFB into cognitive therapy to treat PTSD is realistic and useful. The study has also confirmed that neuroscience-based cognitive therapy can be successfully applied to patients afflicted by PTSD.

Lowering arousal by improving cortical frontal activity in the brain and lowering the amygdala response can be achieved using both cognitive therapy and applying BFB.

Figure 5, which represents the changes in the EDA (spontaneous phasic activity and tonic activity), demonstrates that some evident neurobiological change occurred in the brain of the patient due to the treatment.

The robust design of this research study, which was
Table 1

*Impact of Events Scale—Revised*

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>n.1</td>
<td>n.2</td>
<td>n.3</td>
<td>n.1</td>
</tr>
<tr>
<td>n.2</td>
<td>n.3</td>
<td>63</td>
<td>61</td>
</tr>
<tr>
<td>n.3</td>
<td>62</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>p</td>
<td>= 0.0001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Figure 1. Impact of Event Scale.*

Table 2

*Beck Anxiety Inventory*

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>n.1</td>
<td>n.2</td>
<td>n.3</td>
<td>n.1</td>
</tr>
<tr>
<td>n.2</td>
<td>n.3</td>
<td>58</td>
<td>56</td>
</tr>
<tr>
<td>n.3</td>
<td>57</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>p</td>
<td>= 0.0001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3

*Beck Depression Inventory*

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>n.1</td>
<td>n.2</td>
<td>n.3</td>
<td>n.1</td>
</tr>
<tr>
<td>n.2</td>
<td>n.3</td>
<td>52</td>
<td>50</td>
</tr>
<tr>
<td>n.3</td>
<td>50</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>p</td>
<td>= 0.0001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4

*SCL*

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>n.1</td>
<td>n.2</td>
<td>n.3</td>
<td>n.1</td>
</tr>
<tr>
<td>n.2</td>
<td>n.3</td>
<td>9,8</td>
<td>11,6</td>
</tr>
<tr>
<td>n.3</td>
<td>12,5</td>
<td>4,1</td>
<td>3,8</td>
</tr>
<tr>
<td>p</td>
<td>= 0.004</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3

Beck Depression Inventory

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n.1</td>
<td>n.2</td>
<td>n.3</td>
</tr>
<tr>
<td>n.1</td>
<td>52</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>n.2</td>
<td>50</td>
<td>52</td>
<td>50</td>
</tr>
<tr>
<td>p</td>
<td>0.0001</td>
<td>0.0001</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Figure 2. Beck Anxiety Inventory.

Figure 3. Beck Depression Inventory.
Table 4

**SCL**

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>n.1</td>
<td>9,8</td>
<td>4,1</td>
<td>2,9</td>
</tr>
<tr>
<td>n.2</td>
<td>11,6</td>
<td>3,8</td>
<td>3,1</td>
</tr>
<tr>
<td>n.3</td>
<td>12,5</td>
<td>3,9</td>
<td>2,8</td>
</tr>
</tbody>
</table>

$p = 0.004$

**Figure 4. SCL (Table 4).**

**MindSCAN**

Confronto di tracciati relativi al monitoraggio della attività elettrodinamica
Laboratorio: Centro Clinico ALETEIA - Enna tel. 0931-22040

**Figure 5. A plot obtained using the program MindSCAN that is included in the MindLAB Set. Copyright by the Institute of Cognitive Science, Enna, Italy.**
carried out according to the guidelines of a single-case research study, and the clear results provide supporting evidence for the protocol.

The protocol, including the MindLAB Set, is inexpensive and easy to apply without any specific training is an added advantage.

In conclusion, the results of this study support neuroscience-based cognitive therapy as a new and useful approach to understanding and treating PTSD. The protocol is both neuroscience- and evidence-based.

References


Scrimalli, T., Tomasello, D., & Sciuto, M. (2015). Integrating electrodermal biofeedback into...
pharmacologic treatment of grand mal seizures. 
*Frontiers in Human Neuroscience*, 9, Article 252.  
doi:10.3389/fnhum.2015.00252

Treatment of Vietnam War veterans with PTSD:  
A comparison of eye movement and reprocessing,  
biofeedback, and relaxation training. *Journal  
jts.2490080212

therapy: Creative and compassionate counseling*.  

World Medical Association. (2013, November  
27). World Medical Association Declaration of  
Helsinki: Ethical principles for medical research  
involving human subjects. *JAMA*, 310, 2191–  
journals/jama/fullarticle/1760318

based practice in biofeedback and neurofeedback*.  
Wheat Ridge, CO: Association for Applied  
Psychophysiology and Biofeedback.

**Conflict of Interest Statement**

The research was conducted in the absence of any  
commercial or financial relationships that could be  
construed as a potential conflict of interest.